Rate My Professor Alain Wuethrich

Associate Professor Alain Wuethrich is an NHMRC Emerging Leadership Fellow and ARC Discovery Early Career Researcher Award (DECRA) recipient at the Centre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology, School of Chemistry and Molecular Biosciences, Faculty of Science, University of Queensland. He obtained his PhD from the University of Tasmania in 2016, after completing a Master’s degree in Switzerland and a Postgraduate Diploma from the University of Tasmania. Following his doctorate, he held a Swiss National Science Foundation Fellowship at the University of Queensland from 2016 to 2018, researching electrohydrodynamic fluid flows for electrochemical biosensing. In 2018, he received a UQ Development Fellowship, enabling him to establish and lead the Wuethrich Group, focusing on diagnostic nanoplatforms for precision medicine, particularly cancer biomarker detection in liquid biopsies. Prior to academia, he worked in international pharmaceutical companies and became the lead inventor on a European patent. Since 2017, he has supervised over 30 postgraduate and graduate students in nanotechnological strategies for detecting cancer and other diseases, and has engaged with national and international companies to translate diagnostic technologies.

Wuethrich’s research centers on developing novel analytical and diagnostic tools that harness nanotechnology and microfluidics for precision medicine applications, including liquid biopsy, biosensing, and extracellular vesicle analysis to monitor cancer progression, immune therapies, protein phosphorylation, and DNA methylation aberrations. His group addresses challenges in biomarker detection for cancer, infectious diseases, and immune dysregulations. Notable publications include 'A Digital Single-Molecule Nanopillar SERS Platform for Predicting and Monitoring Immune Toxicities in Immunotherapy' (Nature Communications, 2021), 'Tracking Extracellular Vesicle Phenotypic Changes Enables Treatment Monitoring in Melanoma' (Science Advances, 2020), 'Multifactor Authentication in Extracellular Vesicle Analysis' (Nature Methods, 2026), 'Glycaemic Variability Underlies Myocyte Dysfunction and Myocardial Injury Risk in Diabetes' (Nature Communications, 2026), and 'Ultrasensitive Multiplex Detection of Lung Cancer EV-Associated Immune Checkpoints Using a Mesoporous Gold Enhanced SERS Biosensor' (Nanoscale, 2025). He has secured funding from NHMRC Investigator Grants, ARC Discovery Projects, Cancer Australia, and UQ Foundation Research Excellence Awards, supporting projects like the Immune Dashboard Chip for Long COVID and nanoIMPAC for lung cancer immune monitoring.